| CERUS CORP. DL-,001 |
| USA |
| Gesundheit |
| US1570851014 / 905249 |
| CU2 (Frankfurt) / CERS (NASDAQ) |
| FRA:CU2, ETR:CU2, CU2:GR, NASDAQ:CERS |
| - |
| https://www.cerus.com/ |
|
Cerus Corporation is a biomedical products company dedicated to enhancing blood transfusion safety through its INTERCEPT Blood System. This platform inactivates a broad range of pathogens, including v..
>Volltext.. |
| 336.6 Mio. EUR |
| 349.2 Mio. EUR |
| 177.42 Mio. EUR |
| -29.44 Mio. EUR |
| -13.45 Mio. EUR |
| -0.07 EUR |
| 83.44 Mio. EUR |
| 17.18 Mio. EUR |
| 4.16 Mio. EUR |
| 0.82 |
| 0.79% |
| 34.15% |
| - |
| - |
| - |
| CERUS |
| 10.03.26 |
|
||||
|